World's Best Scientists 2026 revealed!

D-Index & Metrics

Neuroscience

D-Index
68
Citations
24090
World Ranking
2709
National Ranking
267

Best Publications

  • Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease

    Denise Harold;Richard Abraham;Paul Hollingworth;Rebecca Sims

  • Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.

    Paul Hollingworth;Denise Harold;Rebecca Sims;Amy Gerrish

  • Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease.

    Lesley Jones;Peter A. Holmans;Marian L. Hamshere;Denise Harold

  • Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations

    Lucy Webster;Derek Groskreutz;Anna Grinbergs-Saull Grinbergs-Saull;Rob Howard

  • Abeta-degrading enzymes in Alzheimer's disease.

    James Scott Miners;Shabnam Baig;Jennifer Palmer;Laura E Palmer

  • Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease

    C Cruchaga;CM Karch;SC Jin;BA Benitez

  • Drug repositioning for Alzheimer's disease

    Anne Corbett;James Pickett;Alistair Burns;Jonathan Corcoran

  • Aβ-Degrading Enzymes: Potential for Treatment of Alzheimer Disease

    James Scott Miners;Neil Barua;Patrick Gavin Kehoe;Steven Gill

  • Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment

    Olivia A. Skrobot;Johannes Attems;Margaret Esiri;Tibor Hortobágyi;Tibor Hortobágyi

  • Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier.

    Silke Krol;Richard Macrez;Fabian Docagne;Gilles Defer

  • Is inhibition of the renin–angiotensin system a new treatment option for Alzheimer's disease?

    Patrick Gavin Kehoe;Gordon K Wilcock

  • Cognitive impact of COVID-19: looking beyond the short term.

    Scott Miners;Patrick G. Kehoe;Seth Love

  • Convergent genetic and expression data implicate immunity in Alzheimer's disease

    Lesley Jones;Jean-Charles Lambert;Jean-Charles Lambert;Jean-Charles Lambert;Li-San Wang;Seung-Hoan Choi

  • Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy.

    James Scott Miners;Zoë Van Helmond;Katy Chalmers;Gordon Wilcock

  • Angiotensins in Alzheimer's disease – friend or foe?

    Patrick G. Kehoe;Scott Miners;Seth Love

  • Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes

    Scott Miners;Emma Ashby;Shabnam Baig;Rachel Harrison

  • Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy.

    J S Miners;EL Ashby;Z van Helmond;Katy A Chalmers

  • ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer’s disease

    Charles E. Evans;James S. Miners;Giulia Piva;Christine L. Willis

  • Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis

    Ruth Peters;Ruth Peters;Sevil Yasar;Craig S. Anderson;Craig S. Anderson;Craig S. Anderson;Shea Andrews

  • VEGF-A165b Is an Endogenous Neuroprotective Splice Isoform of Vascular Endothelial Growth Factor A in Vivo and in Vitro

    Nick Beazley-Long;Jing Hua;Thomas Jehle;Richard P. Hulse

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Recently Published Articles